SELECT PUBLICATIONS

Armstrong T et al. Chemotherapy-induced peripheral neuropathy. Oncol Nurs Forum 2005;32(2):305-11. Abstract

Bria E et al. Early switch with aromatase inhibitors as adjuvant hormonal therapy for postmenopausal breast cancer: Pooled-analysis of 8794 patients. Cancer Treat Rev 2006;32(5):325-32. Abstract

Buzdar AU, Cuzick J. Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: Emerging data. Clin Cancer Res 2006;12(3 Pt 2):1037-48. Abstract

Carlson RW et al; National Comprehensive Cancer Network. NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. J Natl Compr Canc Netw 2006;4(Suppl 1):1-26. Abstract

Cuzick J et al. Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen? Br J Cancer 2006;94(4):460-4. Abstract

Ewer MS et al. Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment. J Clin Oncol 2005;23(31):7820-6. Abstract

Forbes JF. The use of early adjuvant aromatase inhibitor therapy: Contributions from the BIG 1-98 letrozole trial. Semin Oncol 2006;33(2 Suppl 7):2-7. Abstract

Gelmon K et al. The role of capecitabine in first-line treatment for patients with metastatic breast cancer. Oncologist 2006;11(Suppl 1):42-51. Abstract

Gerbrecht BM, Kangas T. Implications of capecitabine (Xeloda) for cancer nursing practice. Eur J Oncol Nurs 2004;8(Suppl 1):63-71. Abstract

Goss PE et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97(17):1262-71. Abstract

Gradishar WJ et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23(31):7794-803. Abstract

Heidrich SM et al. Symptoms, symptom beliefs, and quality of life of older breast cancer survivors: A comparative study. Oncol Nurs Forum 2006;33(2):315-22;Abstract 11. 

Howell A et al; ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365(9453):60-2. Abstract

Jackisch C. HER-2-positive metastatic breast cancer: Optimizing trastuzumab-based therapy. Oncologist 2006;11(Suppl 1):34-41. Abstract

Joensuu H et al; FinHer Study investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354(8):809-20. Abstract

Kaufmann M, Rody A. Long-term risk of breast cancer recurrence: The need for extended adjuvant therapy. J Cancer Res Clin Oncol 2005;131(8):487-94. Abstract

Limburg CE. Screening, prevention, detection, and treatment of cancer therapy-induced bone loss in patients with breast cancer. Oncol Nurs Forum 2007;34(1):55-63. Abstract

Mamounas E et al. Association between the 21-gene recurrence score assay (RS) and risk of locoregional failure in node-negative, ER-positive breast cancer: Results from NSABP B-14 and NSABP B-20. Presentation. San Antonio Breast Cancer Symposium 2005;Abstract 29.

Marse H et al. Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda). Eur J Oncol Nurs 2004;8(Suppl 1):16-30. Abstract 3.

Miller KD et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23(4):792-9. Abstract

Owers R. Clinical experience with fulvestrant ('Faslodex'): A nurse's perspective. Eur J Oncol Nurs 2004;8(Suppl 2):89-94. Abstract

Perez EA et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 Intergroup adjuvant trial. J Clin Oncol 2006;24(19):3032-8. Abstract

Robert N et al. Pilot study of dose dense doxorubicin + cyclophosphamide followed by ABI-007 in patients with early stage breast cancer. San Antonio Breast Cancer Symposium 2005;Abstract 2073.

Slamon D et al, on behalf of the BCIRG 006 Investigators. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. San Antonio Breast Cancer Symposium 2005;Abstract 1.

Sternberg CN et al. Development of and clinical experience with capecitabine (Xeloda) in the treatment of solid tumours. Eur J Oncol Nurs 2004;8(Suppl 1):4-15. Abstract

Thürlimann B et al. Guidelines for the adjuvant treatment of postmenopausal women with endocrine-responsive breast cancer: Past, present and future recommendations. Eur J Cancer 2007;43(1):46-52. Abstract